ABSTRACT: Ventricular assist device has rapidly emerged as a durable and safe therapy for end-stage heart failure patients with >22 000 implantations to date. Though originally conceived for bridge-totransplant indication, significant advancements in medical management as well as technology with arrivals of newer generation devices have improved patient outcomes, leading to increasing use as destination therapy. Despite such improvement, however, the burden of adverse events remains significant and defines the most pressing issue in the current state of ventricular assist device therapy. Eventual use of ventricular assist device technology as a comparable alternative to heart transplantation will ultimately rely on our ability to mitigate these risks. Therefore, this review article provides the narrative surrounding the rapid integration of this technology into the heart failure paradigm, specifically in the context of the most recent data on its outcomes and adverse event profiles. It describes ongoing investigations and general trends that may have significant implications for future improvements in device-related outcomes, as the field continues to grow as the epitome of synergy between advancements in engineering and clinical medicine.
M
echanical circulatory support (MCS) with ventricular assist device (VAD) is a safe and efficacious treatment strategy for patients with end-stage heart failure (HF) that is refractory to medical therapy, [1] [2] [3] with >22 000 devices implanted to date in America and >2500 new implants occurring annually. 4 Although these patients appreciate 81% and 70% survival at 1 year and 2 years, respectively, 4 they still experience high rates of VAD-related adverse events (AEs), which require our keen attention and understanding. This manuscript aims to provide a necessary overview regarding the current use of VADs in the treatment of end-stage HF, with a specific focus on AEs.
INDICATIONS AND DEVICE TYPE
The concept of MCS developed concomitantly with the field of heart transplantation (HT), as VADs were originally conceived as temporary, bridge-to-transplant (BTT) platforms. Initially, BTT was an effective strategy to rescue patients whose severity of HF precluded survival on medical therapy alone until a donor organ became available. However, it was recognized early on that utilizing VAD solely as BTT was inadequate in addressing the growing prevalence of end-stage HF. With the annual volume of HT in the U.S. stagnating around 3000, implanting VADs as BTT without addressing this bottleneck only increased the size of the BTT population vying for HT. The proportion of those who received HT as BTT increased from 19.1% in 2000 to 41 .0% in 2012. 5 This epidemiological challenge inspired the utilization of VADs as destination therapy (DT)-potentially a durable, lifelong alternative to HT. 1, 6 Today, as the number of patients who are supported by VADs continues to grow, those indicated as DT constitute ≈50%, whereas BTT constitutes 26%. 4 For the remaining 24%, the other indications include bridge-to-candidacy and bridge-to-decision, which suggest the possibility of transplant evaluation after VAD implantation, and bridge-to-recovery, which offers temporary MCS for the duration of the acute insult.
Successful industry partnerships continue to challenge the boundaries of device design. The REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial in 2001 by Rose et al 1 first demonstrated the potential of using VADs as a durable DT platform with superior survival outcomes compared with conventional medical therapy alone. The trial was initially received with equal parts excitement for the immense potential of this platform and legitimate trepidation over its alarmingly high rates of complications. Since then, the field has undergone several paradigm shifts with commensurate improvements in AE profiles. The early-generation devices were pneumatically driven and pulsatile-flow, which contributed to significant morbidity profiles, including high incidence of device failure and poor survival. Recognizing these limitations, subsequent clinical investigations began to focus on a new design in MCS that would come to actualize its potential as mainstream therapy for HF-continuousflow (CF) devices. Smaller and more durable, their early results demonstrated significantly improved survival and complication profiles, both for BTT and DT patients. 2, 7, 8 As the field transitioned toward CF-VADs, 2 distinct subclassification of CF design also emerged: axial and centrifugal mechanisms. Axial flow is generated by a propeller in a pipe, whereas centrifugal flow is generated by a bladed disk spinning in a cavity. During this era, 2 devices in particular, the axial-flow Heartmate II device (Abbott Laboratories, Abbott Park, IL) and the centrifugal-flow HeartWare HVAD device (Medtronic, Minneapolis, MN) constituted the majority of devices implanted worldwide. The HeartMate II has a cylindrical body that sits in the upper abdominal pocket, whereas the HVAD is a smaller device that is circular and entirely intrapericardial. Both designed to directly unload the LV and to augment cardiac output into the ascending aorta, they can provide full cardiac output, nearing 10 L per minute. Both devices are connected to an external power source via a driveline that is tunneled subcutaneously and exits at the level of the abdomen.
Several key engineering differences between the 2 devices are that the HeartMate II rotor spins on blood-immersed ruby bearings, whereas the HVAD has a magnetically levitated, frictionless rotor. The HVAD's smaller size is theoretically more conducive to biventricular or minimally invasive placement via thoracotomy. The results from the LATERAL trial, which prospectively compared outcomes of HVAD placement using traditional sternotomy versus thoracotomy approaches, will soon be published. Some of the engineering differences between centrifugal and axial flow devices carry important physiological and management implications. 9 Although the effects of different flow-profiles are clinically harder to distinguish than in a laboratory, they point to important considerations for patient management. For instance, centrifugal output is exquisitely sensitive to loading conditions, producing high pump-flow pulsatility in accordance with native ventricular activity. On the contrary, axial output is relatively inelastic across varied pressure gradients, which during low LV volume states, can potentially lead to a higher incidence of suck-down events 9 ( Table 1) . The most recent addition to the field of MCS is a new-generation centrifugal-flow device, the HeartMate III (Abbott Laboratories), which has a fully magnetically levitated rotor, wider blood-flow paths and artificial pulsatility. By programming the device to rhythmically 10 Of note, this manuscript did not aim to directly compare the results between most recent clinical trials using HVAD and Heartmate III devices given the unavailability of primary data for analysis. Nonetheless, the excellent outcomes noted in both trials are emblematic of the exciting engineering potential and ongoing innovation that define this field.
List of Definitions

PATIENT SELECTION AND RISK STRATIFICATION
According to the most recent HF guidelines published by the American College of Cardiology and American Heart Association in 2013, VAD implantation is indicated for patients who have Stage D HF with reduced ejection fraction, which is estimated to include 100 000 to 250 000 patients. 11, 12 However, although the demand is alarmingly high, VAD remains a highly invasive intervention that requires a careful, multidisciplinary evaluation of patients' candidacy before implantation. Numerous studies have reported patient characteristics associated with high risks of AEs and ultimately poor outcome, leading to a general agreement regarding contraindications to therapy ( Table 2) . 13 These broadly include factors which limit life expectancy at the onset, such as ongoing malignancy or irreversible end-organ failure, those which may precipitate AEs postimplantation such as significant pulmonary hypertension or right ventricular (RV) dysfunction, and those which preclude adequate follow-up care such as psychosocial limitations. These boundaries are continually being redrawn as technological progress continues to improve patient outcomes and to diminish the burdens of AE.
Various attempts to stratify risk prior to implantation have been proposed. The most longitudinal and widescale effort to-date has been the use of INTERMACS scale (Interagency Registry for Mechanically Assisted Circulatory Support), which divides advanced HF (New York Heart Association [NYHA] score III-IV) into 7 different risk levels (Table 3) . INTERMACS class 1, the so-called "Crash and Burn" status, comprising approximately 15% of all implantations, signifies highest degree of acuity with critical cardiogenic shock, whereas a score of 7 denotes hemodynamically stable HF with minimal symptoms. Majority of patients receiving VADs are INTERMACS classes 2 (36.4%) or 3 (29.9%). As evidenced by INTERMACS class 1 patients having reduced survival at 1-year compared with class 2 and 3 (74% versus 82%), preimplantation acuity has lasting significant prognostic implications. At the other end of the spectrum, growing evidence suggests that pre-emptively implanting VADs in ambulatory HF patients (INTERMACS classes 4-7), which comprise a shrinking minority (19.4%), have excellent outcomes, approaching 80% to 95% survival at 1-year. [14] [15] [16] Other risk stratification strategies have been proposed, such as the HeartMate Risk Score and recently, the Penn-Columbia Risk Score, utilizing clinical, laboratory, and echocardiographic parameters. 17, 18 In one study, the HeartMate Risk Score was shown to validly risk-stratify patient survival more accurately than INTERMACS class, indicating the potential of increasingly more sophisticated patient selection methods in the future.
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SURVIVAL AND OTHER PARAMETERS
As aforementioned, survival among all CF-VAD patients is currently 81% and 70% at 1 and 2 years postimplanta- tion, respectively. Outcomes are currently more favorable in the BTT than in the DT cohort, with 30% receiving HT at 1-year and 77% surviving to 2 years. Nonetheless, even in the DT population, which inherently possess greater comorbidities that contraindicate them for HT, long-term outcomes are still excellent with 68% overall survival at 2 years. 19 These figures are consistent across the Heartware HVAD and HMII trials; 46% to 59% of them were able to reach the primary composite outcome of survival without disabling stroke or reoperation at 2 years. 12, 14, 20, 21 The Heartmate III cohort recently achieved a 79.5% rate of the same composite outcome, owing to significantly reduced stroke and PT burden. 22 These figures, compared with the trial in 2009 by Slaughter et al, 23 where only 11% of the pulsatile-flow VAD patients were able to reach the composite outcome, convey a narrative of remarkable progress. Although long-term VAD outcomes with 30% survival at 5 years are still inferior to HT, VAD therapy is on the right trajectory to become an equivalent alternative in the future. Their 6-minute walk test distances also doubled from baseline and were sustained at 24 months. Quality of life postimplantation was also evaluated using the Minnesota Living with Heart Failure, Kansas City Cardiomyopathy, and EQ-5D questionnaires. 2, 10, 24 Across all trials, patients experienced immediate and sustained improvements in their quality of life parameters by a significant margin. As VAD use, especially for DT, continues to grow more prevalent, these measures help ensure meaningful survival, in addition to extension of life.
ADVERSE EVENTS
If the previous decade of MCS can be characterized by incremental progress in survival and durability, the overarching challenge of the next will be to neutralize the still high burden of AEs. Despite marked improvements in device design and clinical management, AEs still occur frequently at all time points, with 31% of the patients who survive the index operation being readmitted within 30 days. 19 According to the 8th annual INTERMACS report, 60% of the patients are rehospitalized at least once by 6 months postimplantation. 4 At 1 year, rate of rehospitalization has been estimated to be as high as 65% to 80%, a figure which has remained relatively stagnant for both axial and centrifugal-flow devices. 25, 26 All AEs are major harbingers of morbidities. Stroke and multi-system organ failure have been identified as major causes of early death. Additionally, the rate of rehospitalization has not only profound clinical, but also economic and ethical implications. 27, 28 All of these domains warrant critical investigation going forward. Being in a state of cardiogenic shock (INTER-MACS 1) at time of implantation has been correlated with higher risks of AEs, as would be expected. However, even among healthier patients who are not dependent on IV inotropic support at the time of implant (INTERMACS 4-7) , the ROADMAP trial demonstrated unacceptably high morbidity at 1-year follow-up with 80% readmission rate. 19 Though VAD therapy may improve functional capacity and quality of life in this cohort, the concomitantly elevated burden of AEs ought to be an important consideration in the extension of MCS to a wider, ambulatory HF patient population. 22 Preexisting severity of illness, organ dysfunction, a hybrid physiology rendered complex by the need for anticoagulation predispose VAD patients to high rates of AEs. These include bleeding, infection, sepsis, rightheart failure (RHF), PT, stroke, and aortic insufficiency (AI ; Table 4 ). Notably, concomitant risks of PT, bleeding, and stroke represent the complex hematologic challenges inherent in MCS, simultaneously manifesting as increased bleeding risks and hypercoagulability.
RIGHT HEART FAILURE
The vexing combination of existing RV dysfunction, pulmonary hypertension, and acute hemodynamic shifts often precipitates RHF early on post-VAD implantation in ≈15% to 25% of the patients with 4% requiring RVAD implantation within 2 weeks. 4, 29, 30 Though its exact mechanism is unclear, it is believed to be driven by sudden increases in LV unloading and RV preload, which distorts RV geometry and unmasks underlying dysfunc- Although most cases of RV dysfunction improve with inotropic support, early RVAD utilization is associated with better prognosis in refractory cases. 32 Planned bi-VAD implantation in patients with high-risk of RHF may help mitigate the described hemodynamic challenges in the early postoperative period, though it remains to be studied prospectively. Impella RP (Abiomed, Danvers, MA) is a percutaneous, partial-support device that was approved by the Food and Drug Administration (FDA) in 2017, which may permit earlier and less invasive utilization in this setting and reduce the number of patients who ultimately require RVAD. 31 Studies regarding its safety and efficacy are ongoing. Recent studies analyzing the timeline of RHF have also identified late-onset RHF as a separate entity, occurring in 10% of patients months to years after VAD implantation. 33 As its onset portends dismal prognosis with 38% survival at 1-year, future studies regarding its cause, precipitating factors, and preventive measures are warranted.
PUMP THROMBOSIS
PT is a multifactorial phenomenon which can result in rapid clinical deterioration and even demand emergent pump exchange. 34 Its occurrence negatively influences survival. Its proposed mechanism involves factors leading to decreased or turbulent flow in the VAD as well as suboptimal anticoagulation. Diagnosis relies on abnormal pump parameters, such as power spikes, elevated hemolytic markers, and evidence of reduced ventricular unloading. 35 Though in the original trials it was relatively infrequent, an unexplained and abrupt increase in its incidence was observed in the early 2010s, showing a drastic rise from 2.2% in 2011 to 8.4% in 2013. 2, 3, 21 Most recent clinical trial data suggest that 10.7% to 12.2% of HeartMate II patients and 4.2% to 6.4% of Heartware HVAD patients experience PT requiring device exchange in 2 years. 8, 10, 36, 37 A recent prospective trial demonstrated that strictly adhering to surgical implantation techniques, anticoagulation regimen, and pump speed (1.9% versus 8.9%) further protect against the risk of PT, though the role of device geometry in relation to the heart remains to be further elucidated. 23, 38 Combined with the results from the MOMENTUM 3 trial, which showed almost no suspected or confirmed PT events at 6 months and at 2 years (1.1%) in the HeartMate III cohort, 10 these results indicate the tantalizing possibility of nearly eliminating PT in the future of MCS.
BLEEDING
Bleeding is the most common complication and cause of readmission after VAD implantation. 23 Of these, gastrointestinal bleeding (GIB) is the most common, occurring in 15% to 30% of patients across all device-types, especially among older patients with previous history. Various mechanisms, such as low-pulsatility, shear-stress leading to acquired von Willebrand deficiency, angiodysplasia (arteriovenous malformation) and anticoagulation have been proposed, with endoscopic or laboratory correlations. 41 Management options, including resuscitation, use of proton pump inhibitors, endoscopic cauterization, and temporary discontinuation of anticoagulation, have demonstrated modest benefit in reducing the overall burden of GIB in this patient population with the recurrence rate estimated around 9%. 42 Of note, these interventions are not risk-free. GIB may require multiple transfusions, which may sensitize BTT patients' panel reactive antibody status against potential donors and ultimately increase waiting time and risk of rejection. Cessation of anticoagulation may increase risks of thromboembolic risk. 24 Although engineering-based approach to reducing GIB have been tried, most recently by introducing intrinsic pulsatility to the HeartMate III, the results did not show improved rates of GIB.
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STROKE
More common among women, stroke is arguably the most debilitating AEs while on VAD, occurring in 13% to 30% of VAD patients. 4, 31, 36, 43 Its occurrence is significantly associated with mortality. 43, 44 The concomitantly elevated risks of ischemic and hemorrhagic strokes represent the vexing hematologic challenges in their management, with ischemic etiology (5.5% annual incidence) being more common than hemorrhagic (3.1%). 44 Mechanism behind ischemic stroke is believed to include embolic sources, such as thrombus deposition at the pump, the aortic valve (AV), inflow, or outflow grafts. 45 Both endovascular and systemic thrombolytic therapy should be considered carefully because of high risk of hemorrhagic conversion in this population. Hemorrhagic stroke is believed to occur secondary to hypertension, endocarditis, and hemorrhagic conversion of ischemic infarcts. Its correlation with coagulopathy is generally inconsistent. 45 Recently, the early results from the ENDURANCE II trial (The HeartWare Ventricular Assist System as Destination Therapy of Advanced Heart Failure) demonstrated equivalent stroke rates between the centrifugal HVAD and the axial HeartMate II as long as hypertension is well controlled. 8, 46 The MOMENTUM trial demonstrated a lower incidence of stroke with the HeartMate III device compared WITH the HeartMate II (10.1% versus 19.2%) at 2 years.
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AORTIC INSUFFICIENCY
Progressive, de novo AI post-VAD implantation is a significant barrier to long-term support, with >30% of the patients reaching moderate or worse AI after 2 years. 47 ,48 AI, which is believed to be caused by the device-generated pressure gradient across the AV leading to AV closure and eventual commissural fusion, results in blood volume recirculation, increased pump work, and HF exacerbation. Speed optimization or maintenance of pulsatility, whether it be native or device-generated, to ensure AV opening also appears to be protective by preserving the integrity of AV structure and function. As the Heartmate III device is capable of artificial pulsatility, the degree to which this feature protects against de novo AI remains to be explored. Surgical options for AI, such as AV closure using Park stitch or replacement, are available but appears to increase risk of mortality, whether it is performed concomitantly at the time of VAD implantation or on development of hemodynamically significant de novo AI with VAD. 49 Off-label use of transcatheter aortic valve replacement technology for this indication has been noted in isolated case reports, but remains to be further studied.
50
DRIVELINE INFECTION
Infection is a common VAD-related AE and an independent predictor of mortality. 4 Though it may occur at any aspect of the VAD apparatus ranging from local to systemic, driveline infection in the soft tissues surrounding the outlet is the most common, occurring in 15.4% TO 23.8% in recent CF-VAD cohorts. 8, 10 Compared with the 41% originally reported in the REMATCH trial, this marks a remarkable improvement. Colonization with local flora, which begins locally during or after implant, may progress to a systemic infection without adequate recognition and treatment, conferring significant morbidity. Gram-positive cocci, particularly Staphylococcus epidermidis and aureus, are the most commonly identified pathogens, although Gram-negative rods, such as Pseudomonas and Klebsiella, fungi, and mycobacterium are also associated. 51 Those with abilities to form bio-films are particularly virulent. In addition to usual risk factors for infection, several mechanical and patient-specific factors render VAD patients particularly conducive to driveline infection. The percutaneous driveline can be an ideal gateway for pathogens, especially in this patient population that is often critically ill, immune-compromised, or malnourished. As the mechanism of infection is direct, excellent hygiene is imperative in addition to preoperative antibiotic therapy and avoidance of hematomas, which can be a nidus for infection. Early recognition and aggressive treatment are essential in preventing rapid dissemination of pathogen, which may ultimately require device exchange.
FUTURE DIRECTIONS
As we have observed multiple meaningful paradigm shifts in MCS over the past decade, the following de-cade has the potential to significantly further advance the field of MCS. Here we describe a few foreseeable trends.
Continued Innovation in Device Engineering
While the Heartmate II, III and HVAD devices are the only commercially FDA-approved adult options in North America and constitute the largest percentage of devices implanted to date, the field of MCS is a global phenomenon undergoing constant innovation with varying approvals for clinical use in other continents such as Europe or Asia. In addition to INTERMACS, international research efforts based on high-volume experiences, such as those captured in the EUROMACS (European Registry for Patients with Mechanical Circulatory Support), have led to significant contributions to the field. In this era of robust innovation and collaboration, numerous devices with respective engineering advantages are competing to create the most effective and safest interface including the INCOR (approved in EU; Berlin Heart, Berlin, Germany), Jarvik 2000 (approved in EU; ongoing DT trial in U.S.; Jarvik Heart Inc, New York, NY), EVAHEART LVAS (ongoing BTT trial in U.S.; EVAHEART, Houston, TX), and more. The total artificial heart (TAH; SynCardia, Tucson, AZ) is the only FDA-approved device in its class allowing native heart explantation. Utilized in select patients with biventricular HF, these have been implanted in <2% of the MCS population to-date and currently portend <60% survival at 1 year. 52 Similar devices such as the CARMAT bioprosthetic artificial heart (CARMAT, Velizy Villacoublay), which is a hydraulic, pulsatile device comprising 2 ventricles and 4 bioprosthetic valves, and BiVACOR TAH (BiVACOR Inc, Houston, TX), which is a rotary pump with 2 centrifugal impellers, are currently in the pipeline undergoing clinical investigation and may immensely expand the potential of artificial heart technology.
Although investigational and commercial uses of devices significantly vary and are constantly evolving, the general trajectory of the industry follows several key biomedical principles that are essential to the future of MCS. These broadly include increased durability, biocompatibility, and less invasiveness, both in terms of device profiles and implantation strategies. These advances have the potential to not only improve survival but also to significantly reduce AEs. These concepts are described in detail in the following sections.
Over the ensuing decade, as MCS utilization continues to increase with new generations of devices and engineering concepts, the clinical trial environment must commensurately grow more robust. Despite tremendous opportunities for research in MCS, an estimated <1% of VAD patients currently enter into clinical trials. Thus, the responsibilities of the academic community to advocate for, to design, and to engage patients in clinical trials where there is equipoise will only continue to grow, with an increasingly multidisciplinary approach. In addition to simply studying new devices, other topics of interest to the community include their medical management, such as determining the appropriate heart failure medication or anticoagulation regimen that is tailored to patient profiles.
Miniature, Minimally Invasive
In a remarkably brief time span, the scientific community has observed the rapid miniaturization of machines. Just as the gargantuan computers of the 20th century have become smartphones that fit inside our pockets, so too have the original extracorporeal VADs become today's implantable, intrapericardial devices. Over the following decades, this trend will only continue to quicken. An ongoing clinical trial is investigating the efficacy of the HeartWare miniaturized ventricular assist device system (MVAD), which is an axial-flow device that can generate full cardiac output despite being a third of the size of the HVAD device. Miniaturization also lends itself to more minimally invasive operative techniques. Numerous studies have described thoracotomy-based approaches for device implant and exchange with less perioperative morbidity. The LATERAL trial has finished enrollment and is awaiting publication on the safety and efficacy of HVAD implantation via thoracotomy instead of median sternotomy. The Impella device can be installed percutaneously, though in its current state it comes at the cost of reduced durability, stability, and strength. Be that as it may, these exciting trends foreshadow a not-too-distant future where miniature, minimally invasive VADs will become the standard of care, rendering it widely available to patients at considerably lower risks.
Interplay Between Innovative Engineering and Medical Management
Ultimately, success in long-term utilization of VAD as an alternative to HT will be predicated on our ability to minimize AEs, gleaning insights from interplay between design innovation and improvements in clinical management. The HeartMate III device and its improved hemocompatibility profile is a timely example. As novel engineering features in the HeartMate III have led to significant reductions in the incidence of PT, it opens up an array of potential ways to fine-tune and to study innovative anticoagulation or device-management strategies. 20 These changes may improve on the device's intrinsic hemocompatibility even further, promoting synergy between medical providers and the industry.
Similarly, imminent technological breakthroughs may have significant implications for infection rates. As devices become totally implantable with transcutaneous recharging capabilities, rates of driveline infection will by design be eliminated. Several device companies, through strategic partnerships, are currently working to develop a wireless VAD power delivery system, using technologies such as magnetic resonance coupling. Battery capabilities are also improving rapidly enabling greater efficiency even at more compact scales. Although it is not clear when VADs will become fully wireless, once released, their impact on patient care will be immediate.
STATE OF THE ART
Evolving biventricular support paradigms, including the Total Artificial Heart (TAH), may reduce or prevent RHF altogether and potentially offer MCS therapy to patients with anatomic contraindications to VAD placement such as diastolic HF, noncompaction HF, or other congenital abnormalities. In a cohort of predominantly INTERMACS class I (91%) patients, TAH successfully bridged 68% to HT with reasonable long-term outcomes post-HT (41% at 10 years). 52 Based on the remarkable trajectory of VAD technology over the past several decades, highlighted by incremental advancements in and synergy between engineering and medical management, the future potential of these newly emerging, innovative solutions is bright and limitless.
Cost
Cost of care is a major global future challenge. This issue is particularly salient in the field of MCS given its rapidly increasing usage worldwide and the inherently high cost of device implantation and management. The original REMATCH trial data reported an incremental cost-effectiveness ratio of $802 700 per quality-adjusted life-year. The acquisition cost per Heartmate II was estimated to be nearly $150 000, 53 which led to >$479 million in VAD-related healthcare spending in 2009. 54 Simulated projections comparing the cost-effectiveness of HF treatment strategies using incremental cost-effectiveness ratio have highlighted significantly increased costs attributable to VADs, requiring as much as $200 000 qualityadjusted life-years gained in some studies, which far exceeds those of orthotopic heart transplantation ($97 000) or medical therapy ($54 000). 55, 56 Although VAD technology has undoubtedly been recognized as life-saving therapy, these figures as they currently remain may be prohibitively high to sustain the rapid expansion of its usage. Continued progress in device innovation and medical management will be essential to curbing the cost of this rapidly burgeoning therapy. The cost-effectiveness of VADs is projected to improve as survival and quality of life continue to improve with reduced rates of AEs and readmissions. In the aforementioned study, being able to eliminate these costs led to an estimated reduction in the overall incremental cost-effectiveness ratio of VAD therapy by ≈40%, 55 which highlights the magnitude of potential future savings.
CONCLUSIONS
In a remarkably short span of time, MCS using VAD has become a mainstream treatment option for end-stage HF, with a growing proportion of patients successfully undergoing VAD implantation as DT. Survival outcomes have and will continue to improve with the emergence of newer generations of CF-VADs. Although risks of various AEs are still significant, posing a predominant challenge for the coming decade, altogether, the synergy between medical management and engineering innovations will continue to actualize the unlimited potential of MCS, marking one of the most exciting eras in the treatment of HF. 
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